US › Healthcare

Cytokinetics Inc (CYTK)

US · Healthcare · Biotechnology

$78.61+2.83%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$19.4M
Revenue YoY
+1125.8%
Net profit
$-206.0M
Profit YoY
-27.7%
EPS
$-1.67
EPS estimate
$-1.65
Net margin
-1,064.5%

EPS came in at -1.67 against a street estimate of -1.65 — a miss of 1.2%.

Key statistics

Market cap
$10.38B
Forward P/E
117.6
P/B
60.31
Book value
$-6.65
EPS (TTM)
$-6.85
52-week high
$88.31
52-week low
$32.89
50-day MA
$78.58
200-day MA
$67.93
Beta
0.38

Analyst view

Analysts rate Cytokinetics Inc a buy (18 buy, 3 hold, 0 sell out of 21) with an average price target of $107.80.

Shareholding

Insiders
0.67%
Institutions
119.22%

Largest institutional holders

FundStake
T. Rowe Price Investment Management,Inc.12.91%
BlackRock Inc12.19%
Vanguard Group Inc8.87%
FMR Inc7.90%
Wellington Management Company LLP5.90%
Vanguard Portfolio Management, LLC4.30%
State Street Corp4.23%
Vanguard Capital Management, LLC4.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cytokinetics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.